Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 21 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 506260 | NSE: ANUHPHR

Anuh Pharma Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 21, 2024, 9:04 pm

Market Cap 949 Cr.
Current Price 189
High / Low265/140
Stock P/E16.1
Book Value 60.5
Dividend Yield1.32 %
ROCE25.6 %
ROE19.5 %
Face Value 5.00
PEG Ratio1.06

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Anuh Pharma Ltd

Competitors of Anuh Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,465 Cr. 318390/10865.7 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 59.8 Cr. 80.694.9/25.822.9 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 85.5 Cr. 114155/87.012.8 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,221 Cr. 1,0801,335/62031.2 2072.08 %28.1 %21.1 % 2.00
Industry Average19,460.76 Cr1,177.0554.20184.880.33%16.40%16.92%6.61

All Competitor Stocks of Anuh Pharma Ltd

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales117.27108.74131.66128.97116.38115.07138.73157.31161.48149.53172.10163.89137.91
Expenses108.9096.26119.52115.10105.20101.64126.30143.08147.51131.57148.11144.67127.34
Operating Profit8.3712.4812.1413.8711.1813.4312.4314.2313.9717.9623.9919.2210.57
OPM %7.14%11.48%9.22%10.75%9.61%11.67%8.96%9.05%8.65%12.01%13.94%11.73%7.66%
Other Income1.921.910.341.030.962.012.111.043.472.153.662.823.72
Interest0.180.390.58-0.180.060.110.030.020.020.090.140.100.14
Depreciation2.992.972.993.012.422.442.432.412.012.152.202.231.88
Profit before tax7.1211.038.9112.079.6612.8912.0812.8415.4117.8725.3119.7112.27
Tax %21.35%22.12%16.39%26.01%24.12%23.04%22.93%25.08%23.75%22.61%24.46%22.12%22.49%
Net Profit5.598.607.458.937.349.929.319.6211.7513.8319.1115.369.51
EPS in Rs1.121.721.491.781.461.981.861.922.342.763.813.071.90

Last Updated: October 7, 2024, 8:39 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales243266284326206238321307432487527647623
Expenses225242253289183220291284387439476571552
Operating Profit18243138231830234547527672
OPM %7%9%11%12%11%8%9%8%10%10%10%12%12%
Other Income2454875411561212
Interest1111101122110
Depreciation2232222715121098
Profit before tax18253238282332193939477875
Tax %29%31%31%32%27%29%28%25%26%22%24%23%
Net Profit13182226201723142831366058
EPS in Rs2.503.514.395.154.003.304.662.865.686.107.2211.9911.54
Dividend Payout %40%37%27%24%31%42%29%48%26%29%28%21%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)38.46%22.22%18.18%-23.08%-15.00%35.29%-39.13%100.00%10.71%16.13%66.67%
Change in YoY Net Profit Growth (%)0.00%-16.24%-4.04%-41.26%8.08%50.29%-74.42%139.13%-89.29%5.41%50.54%

Anuh Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:9%
5 Years:15%
3 Years:14%
TTM:5%
Compounded Profit Growth
10 Years:12%
5 Years:19%
3 Years:32%
TTM:33%
Stock Price CAGR
10 Years:14%
5 Years:24%
3 Years:22%
1 Year:12%
Return on Equity
10 Years:15%
5 Years:14%
3 Years:16%
Last Year:19%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 5:52 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital44413131313132525252525
Reserves718297107128137152150166189216266278
Borrowings1002024451441314
Other Liabilities60776771485771119128129163152117
Total Liabilities136163168193189209240326333347405446434
Fixed Assets1012918171721847161534946
CWIP30000634000002
Investments19274343706639803143919798
Other Assets104124116131101120147163230243261300288
Total Assets136163168193189209240326333347405446434

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +2151916262749-19295413
Cash from Investing Activity +4-5-12-5-2023-7752-8-431
Cash from Financing Activity +-6-8-8-9-4-5-722-33-19-12-9
Net Cash Flow-02-122-13-502-25

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow17.0024.0031.0036.0023.0016.0026.00-22.0031.0043.0051.0073.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days821028884100109859690102118107
Inventory Days433327357264649890776657
Days Payable86102797710210589166133117139105
Cash Conversion Cycle393336427068612848624658
Working Capital Days454243517983704468706168
ROCE %26%31%33%35%19%14%19%10%16%18%19%26%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters70.45%70.43%70.59%70.59%70.59%70.59%70.59%70.59%69.94%69.91%69.91%69.91%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.03%0.03%0.02%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.10%0.00%0.00%
Public29.55%29.56%29.42%29.41%29.40%29.40%29.39%29.40%30.05%29.96%30.05%30.06%
No. of Shareholders21,50021,12320,74020,45220,47019,96919,42319,06620,51922,23723,49423,910

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue5.005.005.005.005.00
Basic EPS (Rs.)11.987.226.105.675.71
Diluted EPS (Rs.)11.987.226.105.675.71
Cash EPS (Rs.)13.709.158.488.688.52
Book Value[Excl.RevalReserv]/Share (Rs.)58.1148.1442.6638.0464.74
Book Value[Incl.RevalReserv]/Share (Rs.)58.1148.1442.6638.0464.74
Dividend / Share (Rs.)2.502.001.751.502.75
Revenue From Operations / Share (Rs.)129.11105.2697.1186.20122.51
PBDIT / Share (Rs.)17.4111.4510.3911.0010.77
PBIT / Share (Rs.)15.709.528.007.997.96
PBT / Share (Rs.)15.639.477.817.697.64
Net Profit / Share (Rs.)11.987.226.105.675.71
PBDIT Margin (%)13.4810.8710.6912.768.78
PBIT Margin (%)12.159.048.239.276.49
PBT Margin (%)12.108.998.038.926.24
Net Profit Margin (%)9.286.856.276.584.66
Return on Networth / Equity (%)20.6214.9914.2914.918.81
Return on Capital Employeed (%)26.8419.5718.5320.7312.18
Return On Assets (%)13.478.938.808.544.38
Total Debt / Equity (X)0.010.000.010.070.27
Asset Turnover Ratio (%)1.521.401.431.311.08
Current Ratio (X)2.201.911.981.701.37
Quick Ratio (X)1.711.461.371.120.99
Inventory Turnover Ratio (X)6.624.944.364.534.59
Dividend Payout Ratio (NP) (%)16.6824.2324.590.0096.33
Dividend Payout Ratio (CP) (%)14.6019.1117.670.0064.58
Earning Retention Ratio (%)83.3275.7775.410.003.67
Cash Earning Retention Ratio (%)85.4080.8982.330.0035.42
Interest Coverage Ratio (X)246.74262.7754.1636.8834.06
Interest Coverage Ratio (Post Tax) (X)170.85166.6632.8020.0319.06
Enterprise Value (Cr.)1223.09392.34417.88446.02334.07
EV / Net Operating Revenue (X)1.890.740.851.031.09
EV / EBITDA (X)14.026.848.038.0912.38
MarketCap / Net Operating Revenue (X)1.900.750.881.050.95
Retention Ratios (%)83.3175.7675.400.003.66
Price / BV (X)4.231.652.012.371.80
Price / Net Operating Revenue (X)1.900.750.881.050.95
EarningsYield0.040.090.070.060.04

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Anuh Pharma Ltd as of November 21, 2024 is: 192.45

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 21, 2024, Anuh Pharma Ltd is Undervalued by 1.83% compared to the current share price 189.00

Intrinsic Value of Anuh Pharma Ltd as of November 21, 2024 is: 221.76

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 21, 2024, Anuh Pharma Ltd is Undervalued by 17.33% compared to the current share price 189.00

Last 5 Year EPS CAGR: 15.23%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 22.17%, which is a positive sign.
  2. The company has higher reserves (156.85 cr) compared to borrowings (6.92 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (377.46 cr) and profit (37.92 cr) over the years.
  1. The stock has a high average Working Capital Days of 60.33, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 49.25, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
    1. Net Profit Margin: 9.28%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 26.84% (Industry Average ROCE: 16.25%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 20.62% (Industry Average ROE: 16.45%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 170.85
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.71
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 16.1 (Industry average Stock P/E: 43.76)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.01
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Anuh Pharma Ltd. is a Public Limited Listed company incorporated on 19/02/1960 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1960PLC011586 and registration number is 011586. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 486.65 Cr. and Equity Capital is Rs. 25.06 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals3-A, Shivsagar Estate, Mumbai Maharashtra 400018anuh@sk1932.com
http://www.anuhpharma.com
Management
NamePosition Held
Mr. Arun TodarwalChairman & Non-Exe.Director
Mr. Bipin N ShahVice Chairman
Mr. Ritesh B ShahJoint Managing Director
Mr. Vivek B ShahJoint Managing Director
Mr. Sandeep JoshiIndependent Director
Mr. Harmanbhai PatelIndependent Director
Dr.(Ms.) Mita DixitIndependent Director
Mr. Siddharth J ShahIndependent Director
Mr. Pradeep H ThakurIndependent Director
Mr. Ketan ShahNon Executive Director
Mr. Bharat ShahNon Executive Director
Mr. Samir ShahNon Executive Director
Mr. Gaurav S ShahNon Executive Director

FAQ

What is the latest intrinsic value of Anuh Pharma Ltd?

The latest intrinsic value of Anuh Pharma Ltd as on 21 November 2024 is ₹192.45, which is 1.83% higher than the current market price of ₹189.00.

What is the Market Cap of Anuh Pharma Ltd?

The Market Cap of Anuh Pharma Ltd is 949 Cr..

What is the current Stock Price of Anuh Pharma Ltd as on 21 November 2024?

The current stock price of Anuh Pharma Ltd as on 21 November 2024 is ₹189.

What is the High / Low of Anuh Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Anuh Pharma Ltd stocks is 265/140.

What is the Stock P/E of Anuh Pharma Ltd?

The Stock P/E of Anuh Pharma Ltd is 16.1.

What is the Book Value of Anuh Pharma Ltd?

The Book Value of Anuh Pharma Ltd is 60.5.

What is the Dividend Yield of Anuh Pharma Ltd?

The Dividend Yield of Anuh Pharma Ltd is 1.32 %.

What is the ROCE of Anuh Pharma Ltd?

The ROCE of Anuh Pharma Ltd is 25.6 %.

What is the ROE of Anuh Pharma Ltd?

The ROE of Anuh Pharma Ltd is 19.5 %.

What is the Face Value of Anuh Pharma Ltd?

The Face Value of Anuh Pharma Ltd is 5.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Anuh Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE